Obermatt
See Similar Stocks →

Collegium Pharmaceutical

NSQ:COLL · US19459J1043
PharmaceuticalsMedium

360

100
EV / EBIT100
Price / Owner Earnings64
Owner Earnings Yield90
Dividend Yield1
Price/Sales96
EV / Gross Profit85
Price/Book59
Return on Capital89
Cash Return on Capital87
Return on Equity87
EBIT Margin86
Gross Profitability76
Cash Conversion93
Accruals81
Owner Earnings Margin86
Sales growth51
Profit Growth89
Long-Term EPS Growth50
Owner Earnings Growth63
Reinvestment20
Price momentum49
Debt load10
Refinancing16
Debt Payback47
Liquidity60
Analyst ratings36
Opinion Changes50
Price Target Upside57
Market mood65
Value Creation20/20strong value creator
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Collegium Pharmaceutical generates returns well above its cost of capital, the foundation of durable shareholder value.

Profile

CountryUSA
IndustryPharmaceuticals
SizeMedium
TypePublic Company
ExchangeNASDAQGS
Founded2002
Employees409
Websitecollegiumpharma.com
ISINUS19459J1043
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
Pain ManagementPsychiatryGastroenterologyAddictionNeurologyCentral Nervous SystemBiotechnologyLife ScienceMedicalTherapeutics

Description

Collegium Pharmaceutical, Inc. operates as a diversified biopharmaceutical company. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for use in the treatment of attention deficit hyperactivity dis…

Analysis

Hidden champion

Collegium Pharmaceutical, Inc. fits the profile of a hidden champion, yet the market has not awarded it the premium its quality earns.

On valuation, the picture is attractive. The owner-earnings multiple stands at 3.7×; owner earnings: the cash an owner could take out each year.

Growth is moderate; the safety picture is adequate. The company scores 20/20 on our value-creation score: strong value creator.

Flags to be aware of: The financial cushion is thinner than comfortable. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
72
2023202420252026

All-time high

81

Mar 2026

All-time low

49

Jan 2023

Average rank

64

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
96
66
58
66
Price/Earnings
45
96
71
100
Price/Book
59
23
6
44
Dividend Yield
1
1
1
1
Value (overall)
87
63
37
77

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Collegium Pharmaceutical with its peers
Supernus Pharma
NMQ:SUPN
81
CountryUSA
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Zevra Therapeutics
NSQ:ZVRA
92
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Ligand Pharmaceuticals
NMQ:LGND
64
CountryUSA
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Cumberland Pharmaceuticals
NSQ:CPIX
28
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
NRX Pharmaceuticals
NAQ:NRXP
49
CountryUSA
IndustryPharmaceuticals
SizeX-Small
Full Stock Analysis →
Neumora Therapeutics
NSQ:NMRA
9
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →